Approximately 1 in 3-4 patients presenting with an ischemic stroke will also have atrial fibrillation (AF), and AF-related strokes can be effectively prevented using oral anticoagulant therapy (OAC), either with well-controlled vitamin K antagonists (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs). In addition, OAC use (both VKAs and NOACs) is associated with a 26% reduction in all-cause mortality (VKAs) or an additional 10% mortality reduction with NOACs relative to VKAs. The decision to use OAC in individual AF patient is based on the estimated balance of the benefit from ischemic stroke reduction against the risk of major OAC-related bleeding [essentially intracranial hemorrhage (ICH)].
INTRODUCTION
Atrial fibrillation (AF) currently affects at least 33.5 million adults in the world population, not including subclinical or undiagnosed AF cases [1, 2] , and the global prevalence of documented AF is probably underestimated because of limited data outside Europe and North America [1, 3] .
Recent population-based studies and stroke registries consistently report a substantial AF-attributable risk of stroke, particularly in the elderly [4] . Approximately 1 in 3-4 patients presenting with an ischemic stroke will also have AF (either already known or first diagnosed at the time of acute stroke, or documented during the post-stroke monitoring) [4, 5] . In comparison to strokes from other causes, AF-related strokes are more often fatal or associated with greater permanent neurological deficit [6] , but can be effectively prevented using oral anticoagulant therapy (OAC) with well-controlled vitamin K antagonists (VKAs) [7] or non-vitamin K antagonist oral anticoagulants (NOACs) apixaban [8] , rivaroxaban [9] , dabigatran [10] , or edoxaban [11] . The use of OAC is also associated with significant reduction in all-cause mortality in AF patients, by 26% with VKAs vs. control/placebo [7] , and by additional 10% risk reduction with NOACs relative to warfarin according to meta-analysis [12] .
The decision to use OAC in individual AF patient is based on the estimated balance of the benefit from ischemic stroke reduction against the risk of major OAC-related bleeding
[essentially intracranial hemorrhage (ICH)].
Better appreciation of the importance of VKAs' anticoagulation quality [a target time in therapeutic range (TTR) of C70%] and the availability of NOACs (which offer better safety compared to VKAs) [12] have decreased the estimated threshold for OAC treatment in AF patients from 1.7% (as estimated for the VKAs standard treatment) to 0.9% annual stroke risk, assuming that NOACs are available [13] .
Still, contemporary registry-based data show that OAC is often underused in AF patients at increased risk of stroke [14] [15] [16] [17] [18] . The uncertainty whether to use OAC may be particularly pronounced in AF patients with a single additional stroke risk factor, who are often (mis)perceived as having a ''borderline'' or insufficient stroke risk to trigger the use of OAC. Also, there is some inconsistency in formal AF guidelines regarding the use of OAC in this subset of AF patients, as shown in Table 1 [ [19] [20] [21] [22] [23] [24] [25] .
In this review article, we summarize the basic principles of stroke risk stratification in AF patients and discuss contemporary real-world evidence on OAC use and outcomes of OAC treatment in AF patients with a single additional stroke risk factor in various real-world AF cohorts. This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
STROKE RISK STRATIFICATION AND THROMBOPROPHYLAXIS IN PATIENTS WITH ATRIAL FIBRILLATION
Patients with AF have an excessive risk of stroke compared to their counterparts without AF but individual stroke risk is not homogeneous and depends on the presence (or absence) of various stroke risk factors [26] . To facilitate the assessment of AF-related risk of stroke in clinical practice, established clinical stroke risk factors derived from the control or placebo arms of historical trials on stroke prevention in AF [7] or large observational AF cohorts have been combined into various stroke risk scores, such as the CHADS 2 or CHA 2 DS 2 -VASc score [27] (Table 2) , the latter being more inclusive of relevant clinical stroke risk factors in comparison to the CHADS 2 score [28, 29] .
Although simple, the CHADS 2 score has well-recognized limitations [30] including poor identification of AF patients at truly low risk of stroke. For example, it has been shown that patients with a CHADS 2 of 0 (presumably low-risk patients) have had an annual stroke rate as high as 3.2% [28] .
The CHA 2 DS 2 -VASc score has been validated in a number of independent cohorts [28, [31] [32] [33] [34] [35] , and is the recommended tool for stroke risk assessment in most of the latest formal AF guidelines [20, 24] . [44] has been shown to improve the predictive value of clinical risk factor based Congestive heart failure/LV systolic dysfunction Annual stroke rates in AF patients with a single additional stroke risk factor observed in these [37, 54, 56, [58] [59] [60] [61] and other observational cohorts [31, 33, 35, 57, [62] [63] [64] [65] [66] [67] are shown in Table 3 . Overall, the stroke rates ranged from 0.5% to 2.75%, or to 6.60% in the study with the highest annual stroke rate (Table 3) . Such variability in stroke rates most probably results from variable methodology, anticoagulation status, and outcome definitions in the studies [30, 68] . For example, the study by Suzuki et al. was based on non-OAC use at baseline, but OAC status at follow-up was unknown, such that the unusually low stroke event rate could be related to some high-risk patients being started on OAC during follow-up [61].
Friberg et al. showed how variable duration of ''blanking period'' influenced the observed stroke rates (overall, the ischemic stroke rate was 5.4% with no quarantine period, 3.0% with 1-week blanking period, and 2.8% with a 4-week quarantine, which was ultimately used in that study) [66] . Although registry-based studies generally require a quarantine period (during which the events are not counted) to achieve a stable population for long-term follow-up, there is no room for a quarantine period in clinical practice, because the decision to use OAC should be made immediately upon the documentation of AF rather than several weeks or months later.
The event rate in the aforementioned study by Friberg et al. was also influenced by the definition of thromboembolic outcome-it was doubled (from 0.5 to 0.7% to 1.3%) when the outcome of ischemic stroke was combined with non-specified stroke, transient ischemic attack (TIA), or systemic embolism [66] . As a result of a low annual rate of ischemic stroke among AF patients with a single additional stroke risk factor in that study (0.5%) the authors questioned the benefit of OAC in such patients, thus neglecting the importance of reducing other AF-related outcomes such as mortality or systemic embolism. In addition, the study has been criticized for ''conditioning on the future'', since all patients ever given OAC (including the follow-up) were excluded from the analysis, thus introducing a potential selection bias leading to low event rates. The same methodological flaws with ''conditioning on the future'' were apparent in the paper by Aspberg et al. [41] . A more appropriate assessment should be censoring on OAC initiation, as reported by Nielsen et al. [69] .
In another study, which used the outcome of ischemic stroke or systemic embolism, the rates of ischemic stroke and mortality in untreated AF patients without additional stroke risk factors were 0.43% and 3.87%, respectively, whilst the rates in untreated AF patients with a single additional stroke risk factor were 1.50% (ischemic stroke) and 11.30% (death) [ (Table 4 ). In the study from Taiwan, for example, stroke rates among AF patients with a single additional stroke risk factor varied from 1.91% with hypertension to 3.34% with age of 65-74 years [65] . In all studies, age has been consistently identified as the most powerful single stroke risk factor among AF patients with a CHA 2 DS 2 -VASc score of 1 (men) or 2 (women). In Asian AF patients, the risk of stroke substantially increased after the age of 50 years [71] , and in a recent nationwide cohort study of non-anticoagulated Taiwanese AF patients with a single stroke risk factor in addition to sex, even an age of 20-49 years was associated with an annual rate of stroke of 1.33%
[72] (which is above the tipping point for NOACs use).
Overall, despite some heterogeneity in the statistical significance of the relationships of various stroke risk factors with observed stroke rates, the presence of a single CHA 2 DS 2 -VASc stroke risk factor was associated with increased Although VKA therapy is generally very well managed in Sweden in comparison to many other countries [80] , the treatment effect of NOACs compared with VKA for the prevention of stroke and systemic embolism seems consistent regardless of cTTR [81] , related to the observation that there is no significant change in rate of major bleedings across center average TTR and individual TTR quartiles [82, 83] . Moreover, well-managed VKA therapy with a TTR of C70% is often difficult to maintain in clinical practice, as shown in many registry-based studies [84, 85] or even in randomized clinical trials [86] . Even though the median TTR was 73%, a TTR of C70% was achieved in only 55% of the patients [87] . Thus, NOACs may be preferred over VKAs in many clinical circumstances, provided that a good adherence to therapy can be accomplished. An increasing body of evidence suggests that the performance of NOACs in real-world settings is broadly similar to their efficacy and safety in the respective randomized clinical trial [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] .
The outcomes of VKA therapy are highly dependent on the quality of anticoagulation, as measured by individual patient's TTR [84] , and OAC-naive patients are particularly vulnerable to OAC-related serious adverse events (both thromboembolism and bleeding) in the first months of treatment, during the OAC inception period [107] . The SAMe-TT 2 R 2 score, assigning 1 point each to female sex, age of \60 years, history of two or more comorbidities (i.e., hypertension, diabetes mellitus, coronary artery disease/myocardial infarction, peripheral arterial disease, congestive heart failure, previous stroke, pulmonary disease, and hepatic or renal disease) and treatment with drugs interacting with VKAs (e.g., amiodarone) and 2 points each for current or recent tobacco use and non-Caucasian ethnicity, has been shown to have reasonably good predictive ability to identify OAC-naive AF patients who would do well on VKAs (patients with a SAMe-TT 2 R 2 score of 0-2), whilst those with a SAMe-TT 2 R 2 score of [2 should be prescribed a NOAC [108] . The SAMe-TT 2 R 2 score has been shown to be predictive not only of the quality of anticoagulation with VKAs but also of all-cause mortality and composite endpoint of thromboembolic events, major bleeding, and mortality [109] [110] [111] [112] [113] [114] .
Given 
PATIENT VALUES AND PREFERENCES
Although OAC therapy achieves the greatest absolute reduction of stroke risk in AF patients at highest risk of stroke, AF patients at ''low to moderate'' risk of stroke still have a clear positive net clinical benefit from OAC therapy (particularly with NOACs). Nevertheless, in a recent Canadian combined survey on physicians and AF patients [115] the fear of OAC-related major bleeding complications has been ranked as the highest-priority OAC therapy-related consideration by physicians, whilst it was placed at only 5th position by patients (of note, patients were more concerned with interactions of OAC with food and drugs, possibility of rapid reversal of OAC effect in emergency situations, the clinical experience with particular OAC, or the requirement for regular blood testing). Another study using an iPad-facilitated questionnaire revealed that AF patients were willing to suffer four major bleeding events in exchange for preventing just one stroke and, in their view, the treatment threshold for the acceptance of OAC therapy was a minimum absolute stroke risk reduction of 0.8% per year (a number needed to treat 125 AF patients) [116] .
Moreover, all health-related quality of life (QoL) scores (SF36) in a recent study were found to be significantly lower in warfarin-treated versus the NOAC-treated patients, which may be explained by the higher bleeding rates and hospital admissions while on warfarin treatment [117] . Recent survey among European electrophysiology centers showed that practicing European cardiologists were spending a considerable amount of time discussing individual risk profiles and available therapies with their AF patients [118] . In a randomized trial, educational interventions in AF patients resulted in improved quality of oral anticoagulation with VKAs [119] . Engaging AF patients in the informed shared decision-making about OAC therapy (either VKAs or NOACs) facilitates their understanding of treatment and helps in eliciting (and correcting) their possible misperceptions or personal barriers to OAC treatment, thus improving their adherence to therapy and ultimate treatment effects [120, 121] . A questionnaire-based tool facilitating the identification of patients' values and preferences and supporting the decision regarding the use of VKAs or NOACs has been described [122] .
Importantly, the individual risk profile of AF patients initially presenting as a ''borderline'' or ''moderate'' risk category may change over time [123] . Regular clinical follow-up of these patients and periodical re-assessment of individual patient risk profile are mandated, since aging and/or development of cardiac, renal, or other comorbidities may aggravate the patient's stroke or bleeding risk [124] , which could sometimes require adjustments in OAC treatment with respect to the choice of oral anticoagulant drug and appropriate dosing [125] .
CONCLUSION
Patients with non-valvular AF and a single additional stroke risk factor may be denied OAC because of the misperception that their risk of stroke is not sufficiently high to justify the use of OAC (either VKAs or NOACs).
Observational data from real-world AF cohorts show that the annual stroke rates in such patients are higher than in patients with no additional stroke risk factors and are around or 
